Key result
Intravenous or intranasal treatment with the butyrophilin peptide BTN74-90 markedly ameliorated disease activity in MOG-induced experimental autoimmune encephalomyelitis.
Molecular mimicry between the milk protein butyrophilin and MOG can either induce or suppress EAE, suggesting a mechanism by which milk products may modulate pathogenic autoimmune responses in multiple sclerosis models.
May inform MS peptide therapies; animal findings leave open human translation and dietary implications.
Experimental autoimmune encephalomyelitis (EAE) induced by sensitization with myelin oligodendrocyte glycoprotein (MOG) is a T cell-dependent autoimmune disease that reproduces the inflammatory demyelinating pathology of multiple sclerosis. We report that an encephalitogenic T cell response to MOG can be either induced or alternatively suppressed as a consequence of immunological cross-reactivity, or "molecular mimicry" with the extracellular IgV-like domain of the milk protein butyrophilin (BTN). In the Dark Agouti rat, active immunization with native BTN triggers an inflammatory response in the CNS characterized by the formation of scattered meningeal and perivascular infiltrates of T cells and macrophages. We demonstrate that this pathology is mediated by a MHC class II-restricted T cell response that cross-reacts with the MOG peptide sequence 76-87, I GEG KVA LRIQ N (identities underlined). Conversely, molecular mimicry with BTN can be exploited to suppress disease activity in MOG-induced EAE. We demonstrate that not only is EAE mediated by the adoptive transfer of MOG74-90 T cell lines markedly ameliorated by i.v. treatment with the homologous BTN peptide, BTN74-90, but that this protective effect is also seen in actively induced disease following transmucosal (intranasal) administration of the peptide. These results identify a mechanism by which the consumption of milk products may modulate the pathogenic autoimmune response to MOG.
No takes yet. Share an insight, caveat, or question.
Stefferl et al. (2000) studied Experimental autoimmune encephalomyelitis (EAE). Butyrophilin (BTN) peptide BTN74-90 was evaluated on EAE disease activity. Intravenous or intranasal treatment with the butyrophilin peptide BTN74-90 markedly ameliorated disease activity in MOG-induced experimental autoimmune encephalomyelitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: